ABL1 and myeloproliferative disorder: Hydroxyurea (HU) and interferon-α (IFN-α) have been widely used in BCR-ABL-negative MPN to control abundant leukocytosis, circulating blasts, and splenomegaly with complete or partial hematological responses but show a short response duration [26,27].